CYPHERPUNK TECHNOLOGIES INC. annual report, FY2021

Business context and reporting period

Issuer mismatch: The request identifies CYPHERPUNK TECHNOLOGIES INC., but the supplied filing is Leap Therapeutics, Inc. (Nasdaq: LPTX), a clinical-stage oncology biotechnology company. This summary reflects the supplied filing, not the named company. The filing is a Form 10-K for the fiscal year ended December 31, 2021; it reports annual results, not standalone fourth-quarter results.

Leap’s lead candidate is DKN-01, an investigational antibody targeting DKK1, studied in cancer combination and monotherapy trials. It had no FDA-approved products or product sales. DKN-01 had FDA orphan drug designation for gastric and gastroesophageal junction cancer and Fast Track designation for a specified patient population; neither is marketing approval.

Financial performance and position

• Operating loss was $41.4 million in 2021 versus $28.5 million in 2020. Product gross margin is not applicable because the company had no product sales.
• Net loss per share was $0.47 in 2021 versus $0.63 in 2020; 2020 common-stockholder loss included preferred-stock and warrant-related dividends and a beneficial conversion feature.
• Financing activities provided $98.0 million in 2021, principally net proceeds of $96.8 million from a September public offering. The year-end cash increase was $62.8 million.
• Total liabilities were $10.0 million, including accounts payable, accrued expenses and lease liabilities. The filing reports no material borrowings or conventional debt balance.
• Management said year-end cash was expected to fund operating expenses and capital needs for at least 12 months from the filing date. This estimate depends on assumptions and is not a guarantee.

Material changes versus 2020

• R&D expense rose $11.7 million, primarily from DKN-01 activity: manufacturing costs increased $5.3 million, clinical trial costs $3.3 million and payroll and related costs $2.9 million. TRX518 spending fell as active development had been discontinued in 2019.
• Net loss increased $13.1 million, while operating cash use increased $9.2 million.
• Australian R&D incentive income rose to $1.2 million from $0.2 million; foreign currency results shifted from a $0.7 million gain to a $0.4 million loss.
• Common shares outstanding increased from 59.7 million to 88.3 million, largely reflecting the 2021 public offering and warrant exercises.

Outlook, commentary and risks

• Management expects continued operating losses and increased development spending. The filing gives no specific revenue, earnings or clinical-development guidance.
• BeiGene’s agreement covers DKN-01 development and commercialization in Asia excluding Japan, Australia and New Zealand. Leap recognized $1.5 million of license revenue in each year from the $3.0 million upfront payment; no royalties were recorded. Up to $132 million in future option and milestone payments, plus tiered royalties, are contingent and uncertain.
• Clinical results cited are preliminary and generally from small, open-label studies. In a first-line gastric/gastroesophageal junction study, 22 patients completing a full cycle had a reported 68% response rate; overall-survival data had not yet matured. These findings do not establish efficacy or approval.
• Key risks include clinical failure or delays, regulatory uncertainty, patient enrollment, reliance on contract manufacturers and research organizations, possible COVID-19 disruptions, competition, intellectual-property challenges, financing needs and dependence on BeiGene’s decisions and performance.
• The company has $5.0 million of manufacturing commitments and $0.7 million for preclinical studies. It reported no material legal proceedings. Disclosure controls and internal control over financial reporting were assessed as effective by management; the filing did not include an auditor attestation of internal controls.

Most important facts for investors to verify

1. Confirm the filing’s issuer: the supplied 10-K is for Leap Therapeutics, not Cypherpunk Technologies.
2. Review the underlying audited statements, cash balance, operating cash burn and management’s 12-month runway assumptions.
3. Check the status, enrollment, endpoints and subsequent results of DKN-01 trials; distinguish preliminary findings from controlled, confirmatory evidence.
4. Verify BeiGene’s option status, development responsibilities, potential payments and any subsequent agreement changes.
5. Assess dilution: 88.3 million common shares were outstanding at year-end, and the filing listed substantial outstanding warrants and equity awards.